Uppsala, Sweden, 2011-12-08 08:53 CET (GLOBE NEWSWIRE) --
THE PERIOD May 1– October 31, 2011
- Consolidated net sales amounted to € 99 thousand (5)[1]
- Operating income amounted to € -3,186 thousand (-2,997)
- Net income after tax amounted to € -3,180 thousand (-3,194)
- Earnings per share was € -0.06 (-0.08)
- Comprehensive income amounted to € -3,180 thousand (-3,194)
SECOND QUARTER August 1– October 31, 2011
- Consolidated net sales amounted to € 0 thousand (0)
- Operating income amounted to € -1,483 thousand (-1,754)
- Net income after tax amounted to € -1,489 thousand (-1,854)
- Earnings per share was € -0.03 (-0.05)
- Comprehensive income amounted to € -1,489 thousand (-1,854)
- Oasmia carries out a SEK 48 million private placement with a new strategic owner
- Enrolment of 650 patients complete in Phase III study with Paclical®
- The Annual General Meeting elected Joel Citron, Martin Nicklasson, Jan Lundberg and Prof. Dr Horst Domdey as Members of the Board
- The Annual General Meeting made a resolution of authorization corresponding to 15 million shares
- Oasmia and Orion concluded Paclical® collaboration in the Nordic countries
[1] The numbers in parentheses concerns results for the corresponding period previous year
Weine Nejdemo, CFO Oasmia Pharmaceutical, Telephone +46 18 50 54 40, e-mail: info@oasmia.com
